CPA
CLB icon

Capital Performance Advisors’s Core Laboratories CLB Stock Holding History

Capital Performance Advisors’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$408 – 659
2024
Q3 		$408 Buy
+22
New +$442 ﹤0.01% 2338

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital Performance Advisors's CLB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Core Laboratories (CLB) in Q4 2024, closing a stake of 22 shares — an estimated $408 sold.

Capital Performance Advisors first reported a position in CLB in Q3 2024 and held it in 1 quarter. The position peaked at $408 in Q3 2024. 209 funds tracked by Wall St. Rank hold CLB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Core Laboratories position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 22 Core Laboratories shares in Q4 2024, an estimated $408.
  • Capital Performance Advisors first reported a position in Core Laboratories in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Core Laboratories position peaked at $408 in Q3 2024.
  • 209 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.